Ascletis Approved for Taiwan Trial of Interferon-Free HCV Regimen

Ascletis Pharma, a Hangzhou clinical stage biopharma, has been approved to begin a Phase II trial in Taiwan of its dual-drug, interferon-free treatment for chronic hepatitis C. The regimen consists of two Ascletis direct-acting antivirals (DAAs) that will be administered for 12 weeks. "We expect the dual drug regimen will be comparable to Gilead's Harvoni in efficacy and safety," Dr. Jinzi Wu, Founder, Chairman and CEO of Ascletis, told ChinaBio® Today in an exclusive interview. "But because we are a China company, our regimen will be more affordable." More details.... Stock Symbol: (NSDQ: GILD) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.